As healthcare and life sciences depend more heavily on digital data, Deloitte has acquired a player in the data warehousing and analytics business. The move gives the consulting giant the keys to Newton, MA-based Recombinant Data's growing business that serves the data needs of hospitals, research institutions and healthcare companies.
On the life sciences side, Deloitte's buyout brings in assets to capitalize upon a growing trend in personalizing treatments. Recombinant, which will become part of Deloitte Consulting Innovation, provides data warehousing and clinical intelligence that support personalized medicine and translational research, among other things, according to Deloitte's release. Financial terms of the buyout weren't released.
"This development advances our commitment to provide clients with analytics-based solutions as well as insights that stretch across the spectrum of health sectors," Jason Girzadas, U.S. managing principal for Deloitte Consulting to the life sciences and healthcare industry, said in a statement. "We are excited to have Recombinant as an integral part of our national consulting practice and tightly linked to our life sciences and health-care industry group."
Hospitals and other research centers have accumulated an incredible amount of clinical and biological data through studies. And Recombinant offers a variety of software and services to support storage and analysis of the data, which often needs to be sliced and diced to yield insights into personalized medicine and other efforts to advance treatment of patients.
- here's the release